Alnylam Pharmaceuticals (ALNY) News Today $240.01 +2.24 (+0.94%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?April 14 at 3:18 PM | insidermonkey.comTreasurer of the State of North Carolina Increases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Treasurer of the State of North Carolina increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 86,915 shares of the bApril 14 at 5:59 AM | marketbeat.comMorgan Stanley Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $268.00April 14 at 2:51 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given New $268.00 Price Target at Morgan StanleyMorgan Stanley cut their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a report on Friday.April 13 at 11:51 AM | marketbeat.comAlliancebernstein L.P. Decreases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Alliancebernstein L.P. cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,590 shares of the biopharmaceutical company's stApril 13 at 4:20 AM | marketbeat.comLegal & General Group Plc Sells 132,042 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Legal & General Group Plc trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 828,917 shares of the biopharmaceutical compaApril 12 at 5:56 AM | marketbeat.comAlnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at Needham & Company LLCApril 12 at 1:41 AM | americanbankingnews.comMorgan Stanley Keeps Their Hold Rating on Alnylam Pharma (ALNY)April 11, 2025 | markets.businessinsider.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Shares Down 6.6% - Should You Sell?Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Down 6.6% - Should You Sell?April 11, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday.April 11, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Winslow Capital Management LLCWinslow Capital Management LLC lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,020,567 shares of the biopharmaceuticApril 11, 2025 | marketbeat.comAviva PLC Purchases 52,738 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Aviva PLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 215.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 77,244 shares of the biopharmaceutical company's stockApril 10, 2025 | marketbeat.comResona Asset Management Co. Ltd. Makes New $8.64 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Resona Asset Management Co. Ltd. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 36,656 shares of theApril 10, 2025 | marketbeat.comPrudential PLC Raises Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Prudential PLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 41.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,280 shares of the biopharmaceutical company's stock after purchasingApril 10, 2025 | marketbeat.comPharmaceutical stocks recover after Trump's tariff reversalApril 9, 2025 | msn.com2,900 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by ADAR1 Capital Management LLCADAR1 Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,900 shares of the biopharmaceutical company's stock, valued atApril 9, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Increased by Federated Hermes Inc.Federated Hermes Inc. boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 47.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 249,591 shares of the biopharmaceutApril 9, 2025 | marketbeat.comIs Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires?April 8, 2025 | msn.comPolymer Capital Management HK LTD Acquires New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Polymer Capital Management HK LTD bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,313 shares oApril 8, 2025 | marketbeat.comHimension Capital Singapore PTE. LTD. Invests $1.07 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Himension Capital Singapore PTE. LTD. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 4,529 shares of the biopharmaceutical company's stock, valuApril 8, 2025 | marketbeat.comHC Wainwright Issues Optimistic Forecast for ALNY EarningsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities researchers at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research report issued on Wednesday, April 2nd. HC Wainwright analyst P. Trucchio now expects that the bioApril 8, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for ALNY EarningsApril 8, 2025 | americanbankingnews.comLeerink Partnrs Has Negative Outlook for ALNY Q1 EarningsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 2nd. Leerink Partnrs analyst M. ForooharApril 8, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Rhenman & Partners Asset Management ABRhenman & Partners Asset Management AB cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,000 shares of the biopharApril 7, 2025 | marketbeat.comQ1 EPS Estimate for Alnylam Pharmaceuticals Cut by AnalystApril 7, 2025 | americanbankingnews.comLeerink Partnrs Has Pessimistic View of ALNY FY2026 EarningsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Analysts at Leerink Partnrs lowered their FY2026 earnings estimates for Alnylam Pharmaceuticals in a research note issued on Wednesday, April 2nd. Leerink Partnrs analyst M. Foroohar now forecasts that the biopharmaceutical company willApril 6, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by Westpac Banking CorpWestpac Banking Corp lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 83.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,560 shares of the bioApril 6, 2025 | marketbeat.comGeode Capital Management LLC Acquires 59,597 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Geode Capital Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,206,800 shares of the biopharmaceutical company's stApril 6, 2025 | marketbeat.comSchroder Investment Management Group Sells 24,112 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Schroder Investment Management Group reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 50.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,230 shares of the biopharmaceutical compApril 6, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook of ALNY FY2026 EarningsApril 6, 2025 | americanbankingnews.comCanaccord Genuity Remains a Buy on Alnylam Pharma (ALNY)April 5, 2025 | markets.businessinsider.com18,240 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Cinctive Capital Management LPCinctive Capital Management LP bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 18,240 shares of the biopharmaceutical company's stockApril 5, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at HC WainwrightApril 5, 2025 | americanbankingnews.comAlnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday.April 4, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Trexquant Investment LPTrexquant Investment LP lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 51.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,024 shares of the biopharmaceutApril 4, 2025 | marketbeat.comCalifornia Public Employees Retirement System Sells 7,649 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)California Public Employees Retirement System lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 204,132 shares of the biopharmaceutiApril 3, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is Groupama Asset Managment's 7th Largest PositionGroupama Asset Managment boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,528,450 shares of the biopharmaceutical company's stoApril 2, 2025 | marketbeat.comAllstate Corp Makes New $894,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Allstate Corp bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,798 shares of the biopharmaceutical company's stock,April 2, 2025 | marketbeat.comBlair William & Co. IL Reduces Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Blair William & Co. IL lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,962 shares of the biopharmaceutical cApril 2, 2025 | marketbeat.comPrudential Financial Inc. Reduces Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Prudential Financial Inc. trimmed its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 77.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,753 shares of the biopharmaceuticaApril 2, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $342.00Scotiabank lifted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a report on Monday.April 1, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated by Analysts at Redburn AtlanticRedburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a research note on Monday. They issued a "buy" rating and a $353.00 price objective on the stock.April 1, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Stifel Nicolaus Analyst SaysStifel Nicolaus increased their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday.April 1, 2025 | marketbeat.comAIA Group Ltd Sells 5,369 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)AIA Group Ltd decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,848 shares of the biopharmaceutical company's stock aApril 1, 2025 | marketbeat.comRedburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy RecommendationApril 1, 2025 | msn.comCIBC Private Wealth Group LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)CIBC Private Wealth Group LLC reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 203,368 shares of the biopharmApril 1, 2025 | marketbeat.comDnB Asset Management AS Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)DnB Asset Management AS increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 26,733 shares of the biopharmaceutical company's stock after acquiring an additional 1,335 shaApril 1, 2025 | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 94,698 sharesApril 1, 2025 | marketbeat.comAlnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology ...March 31, 2025 | businesswire.comAlnylam price target raised to $345 from $300 at StifelMarch 31, 2025 | markets.businessinsider.com Remove Ads Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.840.80▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼3013▲ALNY Articles Average Week Remove Ads Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Regeneron Pharmaceuticals News Biogen News United Therapeutics News Incyte News BioMarin Pharmaceutical News Exelixis News Neurocrine Biosciences News Exact Sciences News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALNY Stock Free ALNY Stock Alerts